trial

A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia

NCTId NCT02008773
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 170 (actual)
Sponsored by Indiana University
Primary completion 2017-06-20
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
170 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2014-03-26
Primary completion
2017-06-20
Eligibility
ALL · 18 Years · 40 Years

Interventions & indications

Drugs
Valacyclovir HCI 500 mg tablets

Sponsors

Indiana UniversityLead Sponsor
Stanley Medical Research InstituteCollaborator
Sheppard Pratt Health SystemCollaborator
University of Maryland, Baltimore CountyCollaborator
Centers for Behavioral Health, LLCCollaborator
Laureate Institute for Brain Research, Inc.Collaborator
University of Kansas Medical CenterCollaborator
University of California Riverside at C.I. Trials, Inc.-Inland EmpireCollaborator
Yale UniversityCollaborator
Innovative Clinical Research, Inc.Collaborator
Clinical InnovationsCollaborator

Investigators

13
Alan Breier, MDPrincipal Investigator
Faith B Dickerson, PhD, MPHPrincipal Investigator
Robert W Buchanan, MDPrincipal Investigator
Robert Litman, MDPrincipal Investigator
Sheldon Preskorn, MDPrincipal Investigator
Brent Wurfel, MD, PhDPrincipal Investigator
Stephen R. Marder, MDPrincipal Investigator
Keith H. Nuechterlein, PhDPrincipal Investigator
Deepak Cyril D'Souza, MDPrincipal Investigator
Rishi Kakar, MDPrincipal Investigator
Gerald Maguire, MDPrincipal Investigator
Diane Highum, MDPrincipal Investigator

Sites

13 total
Bellflower, United StatesLos Angeles, United StatesRiverside, United StatesSanta Ana, United StatesNew Haven, United StatesLauderhill, United StatesIndianapolis, United StatesIndianapolis, United StatesWichita, United StatesBaltimore, United StatesRockville, United StatesTowson, United States

Linked catalysts

1
A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Ph — primary completion2017-06-20

Facts & assertions

4 sourced
Enrollment
170
Phase
PHASE2
Primary Completion Date
2017-06-20
Status
COMPLETED
relationships
The graph out of here
drug
Valacyclovir HCI 500 mg tablets
drug
lead_sponsor
Indiana University
company
collaborator
Stanley Medical Research Institute
company
Sheppard Pratt Health System
company
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorders
indication
investigator
Alan Breier, MD
person
Faith B Dickerson, PhD, MPH
person
Robert W Buchanan, MD
person
Robert Litman, MD
person